Telomir Pharmaceuticals shares are trading higher after the company reported preclinical data showing Telomir-1 reactivates key tumor suppressor genes via DNA methylation reset in prostate cancer models.

Telomir Pharmaceuticals +3.85%

Telomir Pharmaceuticals

TELO

1.35

+3.85%

Telomir Pharmaceuticals shares are trading higher after the company reported preclinical data showing Telomir-1 reactivates key tumor suppressor genes via DNA methylation reset in prostate cancer models.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via